Clinical Study
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy
Table 1
Clinicobiological characteristics of the patients.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
*Frails due to age higher than 75 years, one refused conventional chemotherapy. **Secondary leukemia following myelodysplasia and not eligible for the available conventional protocols. |